-+ 0.00%
-+ 0.00%
-+ 0.00%

Akebia Therapeutics Doses First Patient In Phase 2 Basket Trial Of Ebribafusp In Rare Complement-Mediated Kidney Diseases

Benzinga·09/14/2026 12:04:34
Listen to the news

Open-label Phase 2 trial evaluating ebribafusp for the treatment of IgA nephropathy, lupus nephritis and C3 glomerulopathy

Initial data is expected in 2027